(MENAFN- Newsfile Corp) Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee:

• On-boarding of all new patients entering Hemostemix treatment programs;
• Comprehensive medical records review and HIPAA-compliant transfer of patient records to the treating physician team;
• Patient health-journey mapping, from initial assessment through treatment and multi-year follow-up;
• Continuous patient data monitoring, including heart rate, activity, exercise, and sleep metrics captured through approved wearable devices such as Fitbit Sense 2;
• Monthly follow-up meetings to support goal setting, healthcare journey adherence, and improvements in functional status;
• Adverse event monitoring, documentation, and reporting, including:
  • Real-time tracking of patient-reported issues;
  • Immediate escalation protocols to the treating physician;
  • Formal reporting to Hemostemix's clinical operations team and regulators.
  • Ensuring compliance with regulatory, clinical, and safety obligations.

Ms. Harding brings more than three decades of patient-hands-on clinical and management experience to her role, which will be leveraged it to advance Hemostemix's personalized care experience in The Bahamas, Florida, and Canada. This integrated role strengthens Hemostemix's hands-on, patient-centric healthcare model. It ensures long-term continuity of care for all who are treated with VesCell. Equally important, it enables patient data capture, which will be used to advance regulatory approval of ACP-01.

"I've known Shaune since 1967," said Thomas Smeenk, President & CEO of Hemostemix. "Shaune has always been one of the best-hearted friends anyone could have. Hemostemix's patients are going to love working with her, as she will help them get assessed, onboard, treated, and followed-up monthly. Shaune is the perfect person to guide patients throughout their health journey, and I'm thrilled to welcome her to head our patient care team," Smeenk said.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCellTM (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit .

MENAFN04122025004218003983ID1110437874